Oncotarget Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy

(Impact Journals LLC) The cover for issue 11 of Oncotarget features Figure 6, 'Effects of AZD8186 in combination with anti-PD1 on syngeneic models,' by Owusu-Brackett, et al.In vitro cell viability assay and immunoblotting demonstrated that PTEN loss was significantly correlated with AZD8186 sensitivity in triple-negative breast cancer cell lines.